|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
TFDP3 regulates the apoptosis and autophagy in breast cancer cell line MDA-MB-231.
|
30235236 |
2018 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Our results showed that TFDP3 expression can induce autophagy by up-regulating the expression of autophagic key protein LC3(MAP1LC3) and increasing the number of autophagosomes during chemotherapy of malignant tumors.
|
30235236 |
2018 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
To further clarify the mechanisms involved in tumor resistance, this study also examined the expression of TFDP3 and tumor cell autophagy regulation; Autophagy helps cells cope with metabolic stress (such as in cases of malnutrition, growth factor depletion, hypoxia or hypoxia) removes erroneously folded proteins or defective organelles to prevent the accumulation of abnormal proteins; and removes intracellular pathogens.
|
30235236 |
2018 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
TFDP3 regulates the apoptosis and autophagy in breast cancer cell line MDA-MB-231.
|
30235236 |
2018 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
These data highlight that TFDP3 is expressed in breast cancer, that it is a member of the cancer-testis antigen family and that it functions as a regulator in epithelial-mesenchymal transition.
|
28114432 |
2017 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Here, we demonstrate that TFDP3 is expressed in a variety of malignancies, normal testis tissue and breast cancer cell lines and thus provide evidence that TFDP3 is a cancer-testis antigen.
|
28114432 |
2017 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
By knocking down the TFDP3 expression level in L-02 and HepG2 cell lines, the cell cycle would be arrested in S phase, which confirmed that TFDP3 can be a potential target for tumor therapy.
|
28797103 |
2017 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
These data highlight that TFDP3 is expressed in breast cancer, that it is a member of the cancer-testis antigen family and that it functions as a regulator in epithelial-mesenchymal transition.
|
28114432 |
2017 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
TFDP3 is a new, promising candidate for transcriptional regulation in breast cancer, although it was first identified in hepatocellular carcinoma.
|
28114432 |
2017 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
HCA661 is a novel cancer/testis (CT) antigen screened by SEREX from sera of an HCC patient.
|
15083197 |
2004 |
|
Malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Transcription factor Dp family member 3 and RAD21 cohesin complex component are important transcription factors in microRNA-21-interfered lung cancer.
|
31506038 |
2019 |
|
Carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Transcription factor Dp family member 3 and RAD21 cohesin complex component are important transcription factors in microRNA-21-interfered lung cancer.
|
31506038 |
2019 |
|
Primary malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Transcription factor Dp family member 3 and RAD21 cohesin complex component are important transcription factors in microRNA-21-interfered lung cancer.
|
31506038 |
2019 |
|
Malnutrition
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To further clarify the mechanisms involved in tumor resistance, this study also examined the expression of TFDP3 and tumor cell autophagy regulation; Autophagy helps cells cope with metabolic stress (such as in cases of malnutrition, growth factor depletion, hypoxia or hypoxia) removes erroneously folded proteins or defective organelles to prevent the accumulation of abnormal proteins; and removes intracellular pathogens.
|
30235236 |
2018 |
|
Neoplasm, Residual
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Collectively, TFDP3 confers chemoresistance in MRD within childhood T-ALL, indicating that TFDP3 is a potential gene therapy target for residual cancer.
|
27902457 |
2017 |
|
Childhood T Acute Lymphoblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, TFDP3 confers chemoresistance in MRD within childhood T-ALL, indicating that TFDP3 is a potential gene therapy target for residual cancer.
|
27902457 |
2017 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, TFDP3 was positive in 23 (62.2%) of 37 prostate cancer samples regardless of stage.
|
24406621 |
2014 |
|
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, TFDP3 was positive in 23 (62.2%) of 37 prostate cancer samples regardless of stage.
|
24406621 |
2014 |
|
Malignant neoplasm of testis
|
0.010 |
Biomarker
|
disease |
BEFREE |
HCA661 is a novel cancer/testis (CT) antigen screened by SEREX from sera of an HCC patient.
|
15083197 |
2004 |
|
Autoimmune Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Further in vivo investigations will clarify, whether the inhibition of the enzymatic activity of DP IV could be a useful tool for therapeutic interventions in MS and/or other autoimmune diseases.
|
10849742 |
2000 |
|
Multiple Sclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Further in vivo investigations will clarify, whether the inhibition of the enzymatic activity of DP IV could be a useful tool for therapeutic interventions in MS and/or other autoimmune diseases.
|
10849742 |
2000 |